Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Down – Here’s Why

Shares of Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) gapped down before the market opened on Thursday . The stock had previously closed at $9.61, but opened at $9.19. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $9.2050, with a volume of 10,709 shares.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. The Goldman Sachs Group upgraded Shionogi & Co., Ltd. Unsponsored ADR to a “hold” rating in a research note on Wednesday, April 8th. Zacks Research lowered Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong sell” rating in a research report on Thursday, April 16th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Shionogi & Co., Ltd. Unsponsored ADR has a consensus rating of “Reduce”.

Shionogi & Co., Ltd. Unsponsored ADR Trading Down 3.1%

The stock has a 50-day moving average of $10.35 and a 200 day moving average of $9.84. The stock has a market cap of $15.85 billion, a PE ratio of 11.64, a price-to-earnings-growth ratio of 0.70 and a beta of 0.10. The company has a quick ratio of 5.21, a current ratio of 5.84 and a debt-to-equity ratio of 0.01.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last issued its earnings results on Tuesday, May 12th. The company reported $0.18 EPS for the quarter, beating analysts’ consensus estimates of $0.15 by $0.03. The firm had revenue of $881.71 million for the quarter, compared to analyst estimates of $895.52 million. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 14.09% and a net margin of 41.08%. As a group, sell-side analysts anticipate that Shionogi & Co., Ltd. Unsponsored ADR will post 0.78 earnings per share for the current year.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company’s product portfolio spans both established and innovative therapies.